Bailard’s Kalaris Therapeutics KLRS Stock Holding History

Bailard’s Portfolio KLRS Stock Details KLRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-952	Closed	-$173K	–	794
2022 Q3	$173K	Hold	952	–	–	0.01%	613
2022 Q2	$85K	Buy	+952	New	+$99.8K	﹤0.01%	665

Other funds holding KLRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Bailard's KLRS Position: Q4 2022 in Review

Bailard sold out of Kalaris Therapeutics (KLRS) in Q4 2022, closing a stake of 952 shares — an estimated $173K sold.

Bailard first reported a position in KLRS in Q2 2022 and held it in 2 quarters. The position peaked at $173K in Q3 2022. 85 funds tracked by Wall St. Rank hold KLRS as of Q4 2022.

Bailard reported no remaining Kalaris Therapeutics position as of Q4 2022 after selling out during the quarter.
Bailard sold 952 Kalaris Therapeutics shares in Q4 2022, an estimated $173K.
Bailard first reported a position in Kalaris Therapeutics in Q2 2022 and held it in 2 quarters.
Bailard's Kalaris Therapeutics position peaked at $173K in Q3 2022.
85 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2022.

Based on Bailard's 13F filing for Q4 2022, filed 2 Feb 2023.